Chat with us

Celnalid 5mg Capsule Bulk Exporter from India to United States | Ernest Impex

📑 Extensive Product Profile: Celnalid 5 mg Capsule

Celnalid 5mg Capsule is a highly advanced, small-molecule immunomodulatory antineoplastic therapeutic formulated for systemic oral oncology care. Developed as a potent derivative of thalidomide, it possesses powerful immunomodulatory, anti-angiogenic, and direct tumor-necrotic properties. Distributed globally to fulfill specialized hospital procurement requirements, international clinical tenders, and clinical setups, it is prescribed by hematonco-specialists worldwide to manage refractory, relapsed, or maintenance-phase hematological malignancies.

Dosage Form: Hard Gelatin Capsules for oral administration
Commercial Strength: 5 mg per capsule
Active Ingredient: Lenalidomide (5 mg)
Primary Manufacturer: Celon Laboratories Ltd.

1. Clinical Indications & Usage

Celnalid 5mg Capsule is an advanced systemic therapy globally indicated for:

Relapsed or Refractory Multiple Myeloma (MM): Indicated for adult patients with advanced multiple myeloma who have received at least one prior therapy, typically administered synergistically in combination with dexamethasone ( $Ld$ or $Rd$ regimens) or as part of triplet protocols to improve progression-free and overall survival rates.
Myelodysplastic Syndromes (MDS): Indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality ( $del(5q)$ ), with or without additional cytogenetic abnormalities.
Mantle Cell Lymphoma (MCL): Indicated for the treatment of patients with relapsed or refractory mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which must have included bortezomib.
Follicular and Marginal Zone Lymphoma: Utilized in combination with rituximab ( $R2$ regimen) for patients with previously treated follicular lymphoma or marginal zone lymphoma.

2. Mechanism of Action: How Celnalid Works

Celnalid functions through a complex, multi-pathway biological framework that exerts direct cytotoxic, anti-angiogenic, and immunomodulatory effects:

Ubiquitin Ligase Binding (Direct Cytotoxicity): Celnalid binds directly to Cereblon (CRBN), a component of the cullin-RING E3 ubiquitin ligase enzyme complex ( $CRL4^{CRBN}$ ). This binding alters the substrate specificity of the ligase, causing the selective polyubiquitination and subsequent degradation of specific lymphoid transcription factors—namely Ikaros (IKZF1) and Aiolos (IKZF3). The depletion of these proteins downregulates key cellular survival mechanisms within malignant B-cells, leading to direct cell-cycle arrest and apoptosis.
Anti-Angiogenesis: It systematically inhibits microvascular endothelial cell migration and network formation, microvessel sprout formation, and blocks the secretion of critical pro-angiogenic factors like Vascular Endothelial Growth Factor (VEGF) and basic Fibroblast Growth Factor (bFGF). This effectively starves the bone marrow tumor microenvironment of the blood supply required for tumor progression.
T-Cell and NK-Cell Activation (Immunomodulatory Action): Celnalid stimulates the proliferation and activation of CD4+ and CD8+ T-cells, enhances the production of Interleukin-2 (IL-2) and Interferon-gamma (IFN- $\gamma$ ), and boosts Natural Killer (NK) cell-mediated cytotoxicity against malignant plasma cells.

3. Administration and Dosing Guide

Administration Route: Celnalid is administered strictly via the Oral Route. The capsules must be swallowed whole with a glass of water. They should never be opened, broken, chewed, crushed, or handled directly if damaged.
Dosing Schedules: Dosing depends strictly on the therapeutic indication and the patient's baseline organ functions:
- Multiple Myeloma: The typical starting dose is 25 mg daily (utilizing higher strength capsules) or 5 mg during adjusted maintenance/renal dosing phases, administered on Days 1–21 of repeated 28-day cycles.
- Myelodysplastic Syndromes: The standard dose is 10 mg or 5 mg daily administered on Days 1–21 or continuously for 28 days of repeated 28-day cycles.
Handling Protocols: Healthcare professionals, caregivers, and patients must avoid touching a broken capsule. If the powder inside contacts skin, wash the area immediately and thoroughly with soap and water.

4. Safety, Side Effects, and Monitoring

Celnalid is an exceptionally potent immunomodulatory agent requiring tight clinical monitoring and adherence to safety registry frameworks.

⚠️ Severe Black Box Warnings & Adverse Reactions: Due to its molecular class, Celnalid carries high structural toxicities and is under restricted global distribution models (such as REMS/Risk Management Programs).

Severe Teratogenicity (Embryo-Fetal Toxicity): Celnalid is a structural analogue of thalidomide and causes severe, life-threatening human birth defects or embryo-fetal demise. It must never be used by pregnant women. Women of childbearing potential must undergo mandatory, regular pregnancy tests and utilize two distinct methods of highly effective, non-hormonal contraception simultaneously. Male patients must use condoms during treatment and for a mandated period following the final dose when interacting with females of childbearing potential.
Hematological Toxicities (Severe Myelosuppression): It induces significant neutropenia (low white blood cells) and thrombocytopenia (low platelets). Complete Blood Counts (CBC) must be checked at baseline, weekly for the first several cycles, and monthly thereafter. Dose delays, reductions, or growth factor support may be required.
Deep Vein Thrombosis (DVT) & Pulmonary Embolism (PE): Celnalid significantly elevates the risk of arterial and venous thromboembolism, particularly when combined with dexamethasone or other chemotherapy agents. Antithrombotic prophylaxis (such as low-dose aspirin or low-molecular-weight heparin) is strongly recommended for eligible patients.
Common Side Effects: Fatigue, diarrhea, muscle cramps, peripheral edema, nausea, upper respiratory tract infections, rash, pyrexia, and localized bone or joint pain.

5. Storage, Stability & Commercial Packaging

Storage Framework: Store Celnalid 5 mg capsules at controlled room temperature between 20°C to 25°C (68°F to 77°F); excursions are permitted between 15°C to 30°C (59°F to 86°F). Protect the product from excessive moisture and heat.
Environmental Safeguards: Keep the capsules inside their original blister strip packs and outer manufacturer carton box until the exact moment of clinical administration to protect the hard gelatin shells from external humidity and environmental exposure.
Indian Export & Bulk Supply Excellence: Ernest Impex acts as a secure international conduit by managing optimized supply logistics for bulk pharmaceutical exports. Utilizing certified protective packaging, calibrated insulation structures, and secure transport channels, we guarantee that Celnalid 5mg Capsules arrive at international clinical destinations with their chemical stability, structural integrity, and clinical efficacy completely intact.

6. Regulatory and Compliance Documentation

ERNEST IMPEX provides an audit-ready compliance framework to facilitate smooth customs and international clinical supply verification:

Authentic Certificate of Analysis (COA) per batch production
Validated Origin Ledger and Batch-Specific Manufacturing Credentials
Global Import/Export Regulatory Compliance Papers

💡 Why Choose ERNEST IMPEX?

Procuring oncology supplies through ERNEST IMPEX ensures uncompromised logistical reliability:

Validated Supply-Chain Integrity
Clear Supply Traceability
Logistical Security

PRESCRIPTION MEDICINE IS : YES

Clinical Disclaimer: This profile is compiled strictly for international wholesale procurement and commercial educational research. Celnalid 5 mg Capsule is a specialized oncology drug available exclusively under clinical authorization (PRESCRIPTION MEDICINE IS YES). It must be handled, dispensed, and utilized solely under the direct guidance of a registered oncology specialist. Celnalid is unsafe for use during pregnancy due to catastrophic risks of embryo-fetal harm or severe structural birth defects. Effective contraception must be strictly implemented by patients during treatment and for the mandated post-final dose period. Breastfeeding is strictly contraindicated during treatment. All cross-border importing processes must comply with the native regulatory frameworks and restricted distribution protocols of the destination country.